CBLC
CBLC (E3 ubiquitin-protein ligase CBL-C) is an enzyme. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer.
Overview
Acts as an E3 ubiquitin-protein ligase, which accepts ubiquitin from specific E2 ubiquitin-conjugating enzymes, and then transfers it to substrates promoting their degradation by the proteasome. Functionally coupled with the E2 ubiquitin-protein ligases UB2D1, UB2D2 and UB2D3. Regulator of EGFR mediated signal transduction; upon EGF activation, ubiquitinates EGFR.
CIViC holds 1 clinical evidence item and 0 assertions across 1 variant, naming Olaparib.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · CBLC (E3 ubiquitin-protein ligase CBL-C) is an enzyme. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer.
- 1 · What it is
CBLC (E3 ubiquitin-protein ligase CBL-C) is an enzyme. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer.
- 2 · What goes wrong in cancer
Acts as an E3 ubiquitin-protein ligase, which accepts ubiquitin from specific E2 ubiquitin-conjugating enzymes, and then transfers it to substrates promoting their degradation by the proteasome.
- 3 · How drugs use it
No product in this corpus aims at CBLC yet. Inhibitors are shaped to fit the enzyme's active site so the reaction the cancer relies on stops.
External identifiers
Sources: HGNC HGNC:15961 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q9ULV8 (protein name, function text, keywords and locations (REST API)); CIViC gene CBLC (1 evidence items, 0 assertions, 1 variants; diseases: Breast Carcinoma (GraphQL API, CC0))
Biology
Acts as an E3 ubiquitin-protein ligase, which accepts ubiquitin from specific E2 ubiquitin-conjugating enzymes, and then transfers it to substrates promoting their degradation by the proteasome. Functionally coupled with the E2 ubiquitin-protein ligases UB2D1, UB2D2 and UB2D3. Regulator of EGFR mediated signal transduction; upon EGF activation, ubiquitinates EGFR. Isoform 1, but not isoform 2, inhibits EGF stimulated MAPK1 activation. Promotes ubiquitination of SRC phosphorylated at 'Tyr-419'. In collaboration with CD2AP may act as regulatory checkpoint for Ret signalling by modulating the rate of RET degradation after ligand activation; CD2AP converts it from an inhibitor to a promoter of RET degradation; the function limits the potency of GDNF on neuronal survival. Locus 19q13.32 (HGNC).
- Breast cancer: CIViC evidence names this disease
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: CIViC lists 1 therapies; CIViC holds 1 clinical evidence items on its variants. Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
Latest papers
topQuery for this target: (TITLE:"CBLC" OR ABSTRACT:"CBLC" OR TITLE:"Cbl proto-oncogene C" OR ABSTRACT:"Cbl proto-oncogene C" OR TITLE:"E3 ubiquitin-protein ligase CBL-C" OR ABSTRACT:"E3 ubiquitin-protein ligase CBL-C" OR TITLE:"CBL-3" OR ABSTRACT:"CBL-3" OR TITLE:"CBL-SL" OR ABSTRACT:"CBL-SL" OR TITLE:"RNF57" OR ABSTRACT:"RNF57") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about CBLC, not a curated reading list.